| 3.0799 0.01 (0.32%) | 04-26 13:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.51  |
1-year : | 5.19 |
| Resists | First : | 3.86 |
Second : | 4.44 |
| Pivot price | 3.21 |
|||
| Supports | First : | 2.92 | Second : | 2.43 |
| MAs | MA(5) : | 3.17 |
MA(20) : | 3.35 |
| MA(100) : | 3.69  |
MA(250) : | 3.77 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 19.2 |
D(3) : | 25.4 |
| RSI | RSI(14): 32.9 |
|||
| 52-week | High : | 5.65 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GANX ] has closed above bottom band by 13.5%. Bollinger Bands are 53.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.24 |
| Low: | 2.91 - 2.93 | 2.93 - 2.95 |
| Close: | 3.04 - 3.07 | 3.07 - 3.1 |
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Thu, 25 Apr 2024
Gain Therapeutics' (GANX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Wed, 24 Apr 2024
Gain Therapeutics reports promising Phase 1 results for Parkinson's drug - Investing.com South Africa
Tue, 23 Apr 2024
Gain Therapeutics (NASDAQ:GANX) Earns Outperform Rating from Oppenheimer - MarketBeat
Wed, 17 Apr 2024
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher - Yahoo Finance UK
Mon, 01 Apr 2024
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as ... - The Bakersfield Californian
Mon, 01 Apr 2024
Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 1.426e+007 (%) |
| Held by Institutions | 16.4 (%) |
| Shares Short | 135 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.222e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -40 % |
| Return on Assets (ttm) | 336.8 % |
| Return on Equity (ttm) | -65.2 % |
| Qtrly Rev. Growth | 55180 % |
| Gross Profit (p.s.) | -232.56 |
| Sales Per Share | -329.24 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.67 |
| Dividend | 0 |
| Forward Dividend | 138130 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|